CN1301246C - 1-cyan-1-(3,5-dimethoxy phenyl)-2-(4-R group phenyl ethane and preparation method - Google Patents
1-cyan-1-(3,5-dimethoxy phenyl)-2-(4-R group phenyl ethane and preparation method Download PDFInfo
- Publication number
- CN1301246C CN1301246C CNB2005100390198A CN200510039019A CN1301246C CN 1301246 C CN1301246 C CN 1301246C CN B2005100390198 A CNB2005100390198 A CN B2005100390198A CN 200510039019 A CN200510039019 A CN 200510039019A CN 1301246 C CN1301246 C CN 1301246C
- Authority
- CN
- China
- Prior art keywords
- dimethoxyphenyl
- ethene
- cyano group
- phenyl
- dimethoxybenzeneacetonitrile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present invention relates to 1-cyano-1-(3, 5-dimethoxyphenyl)-2-(4-R group phenyl) ethylene and a preparation method thereof, which belongs to the field of organic chemistry and pharmaceutical chemistry. The 1-cyano-1-(3, 5-dimethoxyphenyl)-2-(4-R group phenyl) ethylene has a general formula referring to the picture, wherein the R represents hydrogen, hydroxyl, nitryl, alkoxyl, carboxyl methoxy group, etc. The compound has the preparation method that 3, 5-dimethoxyphenylacetonitrile reacts with corresponding para orientation R ylbenzaldehyde. The products of the 1-cyano-1-(3, 5-dimethoxyphenyl)-2-(4-R group phenyl) ethylene are derivates of 1, 2-diphenyl ethylene, which are similar to Pterostibene. The compound of the present invention is a new compound which can be used in the medical field of tumor prevention, oxidation prevention, etc.
Description
Technical field
1-cyano group-1-(3, the 5-Dimethoxyphenyl)-2-(4-R base phenyl) ethene and preparation method thereof relates to the derivative of a class stilbene, belongs to organic chemistry and pharmaceutical chemistry field.
Background technology
1989, the epidemiology survey result of world's cardiovascular disorder Controlling System that The World Health Organization (WHO) is presided over showed that Frenchman's evidence of coronary heart diseases and mortality ratio are than other western countries, and be especially much lower than American and Englishman.Although the saturated fatty acid that the Frenchman uses almost is four times in American and Englishman, it is the latter's 1/3rd that the Frenchman suffers from cardiopathic danger.This phenomenon is called as " French antinomy ".Studies show that this phenomenon is that the whole world maximum Production of Wine and country of consumption are closely related with France.Analyze its reason, may be because in fine grape wine, there be a kind of material that is called trans-resveratrol, it has important nourishing function to human body.
Trans-resveratrol (resveratrol, chemical structure is shown in structural formula 1), a kind of derivative of stilbene, its chemistry by name 3,4 ', 5-trihydroxy--trans-stilbene (3,4 ', 5-trihydroxystilbene), be colourless needle crystal, be soluble in organic solvents such as ether, chloroform, methyl alcohol, ethanol, acetone, ethyl acetate.
Resveratrol
resveratrol
Structural formula 1
In the root of Tuber Fleeceflower Root, find trans-resveratrol in 1963 first, in grape vine, also detected this compound in 1976.Found afterwards that it mainly was present in grape leaf and the skin, content is few in the pulp.The trans-resveratrol that approximately contains 50～100mg/g in the fresh Pericarpium Vitis viniferae.At present at least in 72 kind of plant of 31 genus of 21 sections, trans-resveratrol and glucoside thereof have been found.Along with going deep into to trans-resveratrol research, it is found that it has multiple pharmacologically active, as: antitumous effect, influence to cardiovascular systems, anti-microbial effect, in drinks with the collaborative antioxygenation of flavonoid, anti-aging effects, estrogen effect, protect the liver, sharp liver effect, antibechic, antiasthmatic effect, hypotensive activity or the like, particularly result of study shows, trans-resveratrol is promptly initial in 3 stages that cancer takes place, in enhancement and the expansion process, bigger anti-cancer activity is all arranged, and all there is restraining effect etc. in 3 stages that cancer takes place, caused the extensive concern of Chinese scholars.
1997, [Jang M such as Jang, Cai L, Udeani GO, et al.Cancer chemopreventiveactivity of resveratrol, a natural product derived from grapes.Science, 1997,275 (5297): 218] having delivered them on U.S.'s science (Science) magazine is the result of study of object with the mouse, make mouse suffer from skin carcinoma by manual method, it takes resveratrol 2 all reliefs, the back discovery of 18 weeks, cancer cell can reduce 98% at most, minimumly reduces 68%.For the mouse mammary gland culture through carcinogenic processing, trans-resveratrol can suppress the development that preceding infringement takes place tumour in addition.And in mouse skin cancer model, trans-resveratrol can stop the development of tumour.
1998, [Clement MV such as the scientist Clement of NUS, Hirpara JL, Chawdhury SH, et al.Chemopreventive agent Resveratrol, a natural product derivedfrom grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells.Blood, 1998,92 (3): 996] discover, trans-resveratrol can be induced the cracking of human HL60 leukemia cell DNA, and causes membrane phospholipid to lose its asymmetry, shows that trans-resveratrol can induce human HL60 leukemia cell's programmed death.After the trans-resveratrol effect 48 hours, the death of neoplastic cells rate surpasses 80%.Research is also found, cancer cell death depends on the interaction of CD95-CD95L, and trans-resveratrol increases the expression of CD95L in HL60 cell and the T47D mastocarcinoma cell, it is by reaching the purpose of carcinogenic cells in the fatal position to the CD95 of tumour cell and the CD95L expression balance of immunocyte, in case trigger, the CD95 acceptor will activate a series of cascade reactions in the born of the same parents.Scientist finds again with trans-resveratrol mastocarcinoma to be carried out same processing, and the CD95-CD95L system reaches a new level as a result, after 18 hours, can cause 63% T47D mastocarcinoma necrocytosis.These results of study show that the growth effect of mechanism of resveratrol inhibiting cancer cells has more than the cancer that is limited to a certain type.
2000, [Manna SK such as Manna, Mukhopadhyay A, Aggarwal BB.Resveratrolsuppresses TNF-induced activation of nuclear transcription factors NF-kappaB, activator protein-1, and apoptosis:potential role of reactive oxygen intermediates andlipid peroxidation.J Immunol, 2000,164 (12): 6509] and [Holmes-McNary M such as Holmes-McNary, Baldwin AS Jr.Chemopreventive properties of trans-resveratrolare associated with inhibition of activation of the I κ B kinase.CancerRes, 2000,60:3477] find that then resveratrol can block the activation of tumour necrosis factor (TNF) inductive nuclear factor κ B (NF-κ B) with dosage and time-dependent mode, transcribing of the reporter gene that the p65 subunit phosphorylation of inhibition TNF inductive NF-κ B and nuclear translocation and NF-κ B rely on can also be blocked by Buddhist ripple ester, lipopolysaccharides, H
2O
2, inductive NF-κ B such as okadaic acid, ceramide activation, also suppress TNF inductive MAPKK (mitogen activated protein kinase) and the kinase whose activation of c-Jun N-terminal.
Calendar year 2001, [Ahmad N such as Ahmad, Adhami VM, Afaq, et al.Resveratrol causesWAF-1/p21-mediated G (I)-phase arrest of cell cycle and induction of apoptosis inhuaman epidermoid careinoma A431 cells.Clin Cancer Res, 2001,7 (5): 1466] the report resveratrol can inducing cell cyclin deopendent protein kinase (CDK) arrestin p21
WAF-1Generation, and can reduce the protein expression of cyclin (cyclin) D1, D2, E and CDK2, CDK4, CDK6, and then cause the G of people's epidermal carcinoma A431 cell
1Phase pauses, and cell can not be finished from G
1Phase is to the conversion of S phase, and thinks that this process is irreversible, will finally cause apoptosis.
In sum, this extensively is present in the crude substance of occurring in nature resveratrol, has been proved to have comparatively sure antitumor action, is a kind of natural antitumor prodrug that gets a good chance of.But as the medicine of treatment cancer, the effect of resveratrol is strong not enough.Therefore, be necessary its structure is further transformed, in the hope of finding to have the compound of more pretending usefulness.In recent years, existing abroad scholar has begun the research work of resveratrol derivative.2002, [Agnes MR such as American scholar Agnes MR, Muriel C, Cristian D, et al.Cancer chemopreventive and antioxidant activities of pterostibene, a naturallyoccurring analogue of Resveratrol.J.Agric.Food Chem, 2002,50:3453] studied the natural analog 3 of resveratrol, 5-dimethoxy-4 ' '-(pterostibene is as structure for hydroxyl-trans-stilbene
Pterostibene
Structural formula 2
Shown in the formula 2) antitumour activity and anti-oxidant activity.The result shows that pterostibene also has the obvious suppression effect to cyclooxygenase (COX-1).2003, David AL[David A.Learmonth.A concise synthesisof the 3-O-β-D-and 4 '-β-D-glucuronide conjugates of trans-Resveratrol.Bioconjugate Chem.2003,14:262] the 3-position of having reported at resveratrol and 4 '-position introduces the study on the synthesis of glucuronic acid glucoside, in the hope of further its effect of research.
Summary of the invention
The objective of the invention is all have certain antitumour activity based on resveratrol and its analogue pterostibene, and they all belong to 1, the derivative of 2-toluylene, for this reason, design voluntarily and prepared the analogue that a class has the pterostibene of different chemical structures, in the hope of finding to have than the higher anti-tumor activity of Pterostibene or the new compound of anti-oxidant activity.
Technical scheme of the present invention:
The analogue of pterostibene of the present invention is 1-cyano group-1-(3, the 5-Dimethoxyphenyl)-2-(4-R base phenyl) ethene, and its general structure is shown in general structure 3:
General structure 3
R wherein represents hydrogen, methoxyl group, nitro, hydroxyl, carboxymethoxyl etc.
The preparation feedback of the compound of general structure 3 of the present invention is shown in reaction formula 1:
Reaction formula 1
Its preparation method is: with 3,5-dimethoxy benzyl bromine and sodium cyanide carry out cyanation and make 3, the 5-dimethoxybenzeneacetonitrile, 3,5-dimethoxybenzeneacetonitrile and contraposition R benzaldehyde carry out the toluylene reaction and make product 1-cyano group-1-(3, the 5-Dimethoxyphenyl)-2-(4-R base phenyl) ethene.
A, cyanation: 0.2mol sodium cyanide and 50 ml waters are added in the there-necked flask, stir and make the solid dissolving, adds 50 milliliters of dehydrated alcohols, be warming up to 65 ℃, adding 0.2mol 3,5-dimethoxy benzyl bromine was 65 ℃ of insulation reaction 1.5 hours.Reaction solution is poured out, separated out solid after being chilled to room temperature, filter, get white needle-like crystals 3 with the methanol recrystallization, the 5-dimethoxybenzeneacetonitrile;
B. toluylene reaction: in there-necked flask, add 0.02mol 3,5-dimethoxybenzeneacetonitrile, contraposition R benzaldehyde 0.02mol and 20 ml methanol.Stirring is warming up to 60 ℃, adds the 0.02mol sodium methylate, 60 ℃ of reactions 3 hours, separates out solid after being chilled to room temperature, filters, and solid gets 1-cyano group-1-(3, the 5-Dimethoxyphenyl)-2-(4-R base phenyl) ethene with recrystallizing methanol.
Beneficial effect of the present invention: product 1-cyano group-1-(3, the 5-Dimethoxyphenyl)-2-(4-R base phenyl) ethene is the analogue of Pterostibene, in the hope of finding to have the new compound of the antitumor or anti-oxidant activity higher, be used for medical fields such as antitumor, anti-oxidant than Pterostibene.
Specific embodiments
The preparation of embodiment 1:1-cyano group-1-(3, the 5-Dimethoxyphenyl)-2-(4-p-methoxy-phenyl) ethene
3, the preparation of 5-dimethoxybenzeneacetonitrile (1):
9.8 gram sodium cyanides and 50 ml waters are added 250 milliliters of there-necked flasks, stir and make the solid dissolving, adds 50 milliliters of dehydrated alcohols, be warming up to 65 ℃, add 40 and restrain 3,5-dimethoxy benzyl bromine was 65 ℃ of insulation reaction 1.5 hours.Reaction solution is poured out, is separated out solid after being chilled to room temperature, filter, crude product, get white needle-like crystals 23 with the methanol recrystallization and restrain 3,5-dimethoxybenzeneacetonitrile, 51～53 ℃ of fusing points.
The preparation of 1-cyano group-1-(3, the 5-Dimethoxyphenyl)-2-(4-p-methoxy-phenyl) ethene (2a):
At 150 milliliters of there-necked flasks, add 3,5-dimethoxybenzeneacetonitrile (1) 3.54 gram, aubepine 2.72 gram and 20 ml methanol.Stirring is warming up to 60 ℃, adds 1 gram sodium methylate.Continue reaction 3 hours at 60 ℃.Separate out solid after being chilled to room temperature, filter, solid gets colourless acicular crystal 1-cyano group-1-(3, the 5-Dimethoxyphenyl)-2-(4-p-methoxy-phenyl) ethene (2a) 4.8 grams, 117～119 ℃ of fusing points with recrystallizing methanol.
The preparation of embodiment 2:1-cyano group-1-(3, the 5-Dimethoxyphenyl)-2-phenyl ethene (2b)
Adopt embodiment 1 similar method, by 3.54 grams 3,5-dimethoxybenzeneacetonitrile (1) restrains sodium methylate with 2.12 gram phenyl aldehydes and 20 ml methanol, 1, react, get 1-cyano group-1-(3, the 5-Dimethoxyphenyl)-2-phenyl ethene (2b) 2.4 grams, 68～70 ℃ of fusing points.
The preparation of embodiment 3:1-cyano group-1-(3, the 5-Dimethoxyphenyl)-2-(4-nitrophenyl) ethene (2c)
Adopt embodiment 1 similar method, by 3.54 grams 3,5-dimethoxybenzeneacetonitrile (1) restrains sodium methylate with 3 gram 4-nitrobenzaldehydes and 20 ml methanol, 1, react, get golden yellow crystal 1-cyano group-1-(3, the 5-Dimethoxyphenyl)-and 2-(4-nitrophenyl) ethene (2c) 5.5 grams, 214～216 ℃ of fusing points.
The preparation of embodiment 4:1-cyano group-1-(3, the 5-Dimethoxyphenyl)-2-(4-carboxymethoxyl phenyl) ethene (2d)
Adopt embodiment 1 similar method, by 3.54 grams 3,5-dimethoxybenzeneacetonitrile (1) restrains sodium methylate with 3.6 gram 4-carboxymethoxyl phenyl aldehydes and 30 ml methanol, 1, react, get white powder 1-cyano group-1-(3, the 5-Dimethoxyphenyl)-and 2-(4-carboxymethoxyl benzene) ethene (2d) 3.2g, 181～182 ℃ of fusing points.
The preparation of embodiment 5:1-cyano group-1-(3, the 5-Dimethoxyphenyl)-2-(4-hydroxy phenyl) ethene (2e)
Adopt embodiment 1 similar method, by 3.54 grams 3,5-dimethoxybenzeneacetonitrile (1) restrains sodium methylate with 2.4 gram p-Hydroxybenzaldehydes and 30 ml methanol, 1, react, get pale yellow powder solid 1-cyano group-1-(3, the 5-Dimethoxyphenyl)-and 2-(4-hydroxy phenyl) ethene (2e) 1.8 grams, 118～120 ℃ of fusing points.
Claims (7)
1. 1-cyano group-1-(3, the 5-Dimethoxyphenyl)-2-(4-R base phenyl) ethene, its general structure is as follows:
R wherein represents hydrogen, methoxyl group, nitro, hydroxyl or carboxymethoxyl.
2. compound according to claim 1, when R is hydrogen, i.e. 1-cyano group-1-(3, the 5-Dimethoxyphenyl)-2-phenyl ethene.
3. compound according to claim 1, when R is methoxyl group, i.e. 1-cyano group-1-(3, the 5-Dimethoxyphenyl)-2-(4-p-methoxy-phenyl) ethene.
4. compound according to claim 1, when R is nitro, i.e. 1-cyano group-1-(3, the 5-Dimethoxyphenyl)-2-(4-nitrophenyl) ethene.
5. compound according to claim 1, when R is carboxymethoxyl, i.e. 1-cyano group-1-(3, the 5-Dimethoxyphenyl)-2-(4-carboxymethoxyl phenyl) ethene.
6. compound according to claim 1, when R is hydroxyl, i.e. 1-cyano group-1-(3, the 5-Dimethoxyphenyl)-2-(4-hydroxy phenyl) ethene.
7. 1-cyano group-1-(3 according to claim 1, the 5-Dimethoxyphenyl)-preparation method of 2-(4-R base phenyl) ethene, it is characterized in that with 3,5-dimethoxy benzyl bromine and sodium cyanide carry out cyanation and make 3, the 5-dimethoxybenzeneacetonitrile, 3,5-dimethoxybenzeneacetonitrile and contraposition R benzaldehyde carry out the toluylene reaction and make product 1-cyano group-1-(3, the 5-Dimethoxyphenyl)-2-(4-R base phenyl) ethene;
A, cyanation: 0.2mol sodium cyanide and 50 ml waters are added in the there-necked flask, stirring makes the solid dissolving, adds 50 milliliters of dehydrated alcohols, is warming up to 65 ℃, add 0.2mol 3,5-dimethoxy benzyl bromine 65 ℃ of insulation reaction 1.5 hours, is poured out reaction solution, separate out solid after being chilled to room temperature, filter, get white needle-like crystals 3 with the methanol recrystallization, the 5-dimethoxybenzeneacetonitrile;
B. toluylene reaction: in there-necked flask, add 0.02mol 3,5-dimethoxybenzeneacetonitrile, contraposition R benzaldehyde 0.02mol and 20-30 ml methanol, stirring was warming up to 60 ℃, adds the 0.02mol sodium methylate, 60 ℃ of reactions 3 hours, separate out solid after being chilled to room temperature, filter, solid gets 1-cyano group-1-(3, the 5-Dimethoxyphenyl)-2-(4-R base phenyl) ethene with recrystallizing methanol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100390198A CN1301246C (en) | 2005-04-20 | 2005-04-20 | 1-cyan-1-(3,5-dimethoxy phenyl)-2-(4-R group phenyl ethane and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100390198A CN1301246C (en) | 2005-04-20 | 2005-04-20 | 1-cyan-1-(3,5-dimethoxy phenyl)-2-(4-R group phenyl ethane and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1687021A CN1687021A (en) | 2005-10-26 |
| CN1301246C true CN1301246C (en) | 2007-02-21 |
Family
ID=35305063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100390198A Expired - Fee Related CN1301246C (en) | 2005-04-20 | 2005-04-20 | 1-cyan-1-(3,5-dimethoxy phenyl)-2-(4-R group phenyl ethane and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1301246C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1300077C (en) * | 2005-12-07 | 2007-02-14 | 中国科学院广州化学研究所 | Method for preparing resvertrol |
| WO2009146218A2 (en) | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals, Inc. | Compounds including an anti-inflammatory pharmacore and methods of use |
| CN105503652B (en) * | 2015-12-30 | 2017-12-05 | 延边大学 | Cyano-containing resveratrol analogses and its production and use |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1143629A (en) * | 1995-03-07 | 1997-02-26 | 味之素株式会社 | Stilbene derivatives and pharmaceutical compositions containing them |
| CN1455766A (en) * | 2001-01-18 | 2003-11-12 | 维理生物技术公司 | Novel 1,2-diphenylethene derivatives for treatment of immune diseases |
-
2005
- 2005-04-20 CN CNB2005100390198A patent/CN1301246C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1143629A (en) * | 1995-03-07 | 1997-02-26 | 味之素株式会社 | Stilbene derivatives and pharmaceutical compositions containing them |
| CN1455766A (en) * | 2001-01-18 | 2003-11-12 | 维理生物技术公司 | Novel 1,2-diphenylethene derivatives for treatment of immune diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1687021A (en) | 2005-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4397688B2 (en) | Use of stilbene compounds in the manufacture of a medicament for the prevention and treatment of diabetes or retrovirus-related diseases | |
| Gao et al. | Inhibitory effect on α-glucosidase by the fruits of Terminalia chebula Retz. | |
| Qi et al. | Kinsenoside: a promising bioactive compound from Anoectochilus species | |
| CN109824489A (en) | A kind of compound with anti-inflammatory activity extracted from Radix Glycyrrhizae and its application | |
| Wang et al. | Antioxidant activity and inhibition effect on the growth of human colon carcinoma (HT-29) cells of esculetin from Cortex Fraxini | |
| CN101979366A (en) | Diarylheptanoid compounds in curcuma zedoary and medicinal application thereof | |
| Zhou et al. | Semi-synthesis and anti-tumor activity of 5, 8-O-dimethyl acylshikonin derivatives | |
| CN1301246C (en) | 1-cyan-1-(3,5-dimethoxy phenyl)-2-(4-R group phenyl ethane and preparation method | |
| CN100338008C (en) | 1-carboxy-1-(3,5-dimethoxy phenyl)-2-(4-R group phenyl) ethano and preparation method thereof | |
| US20080146659A1 (en) | Hypoglycemic agent, hepatoprotecting agent and anticancer agent containing lignans derived from hongdoushan | |
| CN111135159B (en) | Application of diterpene compound in preparation of tyrosinase inhibitor | |
| CN107722096B (en) | Natural steroid medicine with anti-tumor effect and its prepn and use | |
| CN100368388C (en) | Compounds of resveratrol having nitrile grouping substituent and prepn. process | |
| CN113061124B (en) | Sesquiterpene dimer compound, and preparation method, application and pharmaceutical composition thereof | |
| CN100368373C (en) | Carboxyl substituted resveratrol analog compound and its preparation method | |
| CN111548255B (en) | Diterpenoid compounds in taxus chinensis, preparation method thereof and application thereof in pharmacy | |
| CN109734561B (en) | Farnesyl phenol compound, pharmaceutical composition and application thereof | |
| CN112957352A (en) | Application of natural chlorogenic acid derivative in preparation of ATP citrate lyase inhibitor | |
| KR100619498B1 (en) | Pharmaceutical composition for liver protection and for treating liver disease | |
| CN111233648B (en) | Double chalcone compound and preparation method and application thereof | |
| KR101778082B1 (en) | Pharmaceutical composition comprising caffeic acid reactant for inhibiting Pancreatic lipase | |
| CN112300185B (en) | Alkaloid compound with reduced hepatotoxicity, and preparation method and application thereof | |
| CN107722094B (en) | Natural steroid medicine and its use in preparing antineoplastic medicine | |
| JP2013194044A (en) | New compound having dna polymerase inhibitory activity | |
| CN118908920A (en) | Sesquiterpenoids and extraction method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |